Monique Gannage

Dr. Monique Gannage


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2009 in Cell Host & Microbe
Verified
Journal Article
Closed access
MGMonique Gannage
Monique Gannage
DDDorothee Dormann
Dorothee Dormann
RARandy Albrecht
Randy Albrecht
JDJoern Dengjel
Joern Dengjel
TTTania Torossi
Tania Torossi
Christian MünzChristian Münz
Christian Münz

1 September 2007 in Immunity
Verified
Journal Article
Closed access
GHGuillaume Hoeffel
Guillaume Hoeffel
ARAnne-Claire Ripoche
Anne-Claire Ripoche
DMDiana Matheoud
Diana Matheoud
MNMichelina Nascimbeni
Michelina Nascimbeni
NENicolas Escriou
Nicolas Escriou
CMConcepción Marañón
Concepción Marañón

1 May 2016 in Cell Reports
Verified
Journal Article
Open access
MLMonica Loi
Monica Loi
AMAnne Müller
Anne Müller
KSKarin Steinbach
Karin Steinbach
JNJennifer Niven
Jennifer Niven
RSRosa Barreira da Silva
Rosa Barreira da Silva
MGMonique Gannage
Monique Gannage
The macroautophagy machinery has been implicated in MHC class II restricted antigen presentation. Here, we report that this machinery assists in the internalization of MHC class I molecules. In the absence of the autophagy factors Atg5 and Atg7, MHC class I surface levels are elevated due to decreased endocytosis and degradation. Internalization of MHC class I molecules occurs less efficiently if AAK1 cannot be recruited via Atg8/LC3B. In the absence of Atg-dependent MHC class I internalization, dendritic cells stimulate CD8(+) T cell responses more efficiently in vitro and in vivo. During viral infections, lack of Atg5 results in enhanced influenza- and LCMV-specific CD8(+) T cell responses in vivo. Elevated influenza-specific CD8(+) T cell responses are associated with better immune control of this infection. Thus, the macroautophagy machinery orchestrates T cell immunity by supporting MHC class II but compromises MHC class I restricted antigen presentation.

15 June 2005 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MGMonique Gannage
Monique Gannage
MAMichal Abel
Michal Abel
AMAnne-Sophie Michallet
Anne-Sophie Michallet
SDStépHanie Delluc
StépHanie Delluc
MLMarion Lambert
Marion Lambert
SCSophie Caillat-Zucman
Sophie Caillat-Zucman
Identification of tumor-associated Ags is a prerequisite for vaccine-based and adoptive immune therapies. Some tumor-associated Ags elicit specific CD8 T cells in patients with chronic myeloid leukemia (CML). Here, we characterized ex vivo responses of CD8 T cells from CML patients to extrajunction bcr-abl peptides and telomerase 540–548 hTert, PR1, and WT1 peptides. CML-specific CD8 T cells were present in most treated patients and were usually multiepitopic: WT1, hTert, PR1, and bcr74 tetramer+ cells were detected in 85, 82, 67, and 61% of patients, respectively. The breadth and magnitude of these responses did not differ significantly according to treatment or disease status. CML-specific tetramer+ CD8 T cells had a predominantly memory phenotype, an intermediate perforin content, and low intracellular IFN-γ accumulation in the presence of the relevant peptide. However, in short-term culture with HLA-matched leukemia cells, the patients’ memory T cells were specifically reactivated to become IFN-γ-producing effector cells, suggesting that CD8 T cell precursors with lytic potential are present in vivo and can be activated by appropriate stimulation. In conclusion, this study shows that multiepitopic tumor-specific CD8 T cell responses occur naturally in most CML patients, opening the way to new strategies for enhancing anti-CML immunity, in particular in patients with minimal residual disease.

1 December 2006 in Blood
Verified
Journal Article
Open access
PDF file
MLMarion Lambert
Marion Lambert
MGMonique Gannage
Monique Gannage
AKAlexandre Karras
Alexandre Karras
MAMichal Abel
Michal Abel
CLChristophe Legendre
Christophe Legendre
SCSophie Caillat-Zucman
Sophie Caillat-Zucman
It is unclear how the immune response controls human herpesvirus 8 (HHV8; also known as Kaposi sarcoma–associated herpesvirus [KSHV]) replication and thereby prevents Kaposi sarcoma (KS). We compared CD8 T-cell responses to HHV8 latent (K12) and lytic (glycoprotein B, ORF6, ORF61, and ORF65) antigens in patients who spontaneously controlled the infection and in patients with posttransplantation, AIDS-related, or classical KS. We found that anti-HHV8 responses were frequent, diverse, and strongly differentiated toward an effector phenotype in patients who controlled the infection. Conversely, HHV8-specific CD8 cells were very rare in patients who progressed to KS, and were not recruited to the tumoral tissue, as visualized by in situ tetramer staining of KS biopsies. Last, HHV8-specific CD8 T cells were observed in a seronegative recipient of an HHV8infected graft who remained persistently aviremic and antibody negative, suggesting that specific cytotoxic T lymphocytes (CTLs) may provide protection from persistent HHV8 infection. These results support the crucial role of cellular immune responses in controlling HHV8 replication, in preventing malignancies in latently infected subjects, and in conferring genuine resistance to persistent infection. They may also have important implications for the design of prophylactic and therapeutic HHV8 vaccines, and for adoptive immunotherapy of KS.

1 January 2016 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
JFJean-Francois Fonteneau
Jean-Francois Fonteneau
FBFabienne Brilot
Fabienne Brilot
Christian MünzChristian Münz
Christian Münz
MGMonique Gannage
Monique Gannage
NY-ESO-1–specific CD4+ T cells are of interest for immune therapy against tumors, because it has been shown that their transfer into a patient with melanoma resulted in tumor regression. Therefore, we investigated how NY-ESO-1 is processed onto MHC class II molecules for direct CD4+ T cell recognition of melanoma cells. We could rule out proteasome and autophagy-dependent endogenous Ag processing for MHC class II presentation. In contrast, intercellular Ag transfer, followed by classical MHC class II Ag processing via endocytosis, sensitized neighboring melanoma cells for CD4+ T cell recognition. However, macroautophagy targeting of NY-ESO-1 enhanced MHC class II presentation. Therefore, both elevated NY-ESO-1 release and macroautophagy targeting could improve melanoma cell recognition by CD4+ T cells and should be explored during immunotherapy of melanoma.